Free Trial
LON:HEMO

Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

Hemogenyx Pharmaceuticals logo
GBX 1.55 +0.11 (+7.74%)
(As of 08:28 AM ET)

About Hemogenyx Pharmaceuticals Stock (LON:HEMO)

Key Stats

Today's Range
1.35
1.55
50-Day Range
1.08
1.75
52-Week Range
1
7.13
Volume
4.06 million shs
Average Volume
9.35 million shs
Market Capitalization
£20.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Receive HEMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HEMO Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
See More Headlines

HEMO Stock Analysis - Frequently Asked Questions

Hemogenyx Pharmaceuticals' stock was trading at GBX 2.30 on January 1st, 2024. Since then, HEMO shares have decreased by 32.8% and is now trading at GBX 1.55.
View the best growth stocks for 2024 here
.

Hemogenyx Pharmaceuticals Plc (LON:HEMO) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.20) EPS for the quarter.

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

Last Earnings
9/30/2020
Today
11/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
£-5,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Outstanding Shares
1,340,000,000
Free Float
N/A
Market Cap
£19.23 million
Optionable
Not Optionable
Beta
3.14
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (LON:HEMO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners